Cue Biopharma provides clinical update on CUE-101, saw ORR of 50%

Cue Biopharma (CUE) provided a clinical update on its most advanced asset, CUE-101, representative of the CUE-100 series. Key data highlights from the expansion portion of the trial evaluating CUE-101 at the recommended Phase 2 dose of 4mg/kg in combination with pembrolizumab in 1L patients include: overall response rate, ORR, of 50%. Survival metrics have continued to mature favorably: 12-month overall survival of 88% compared to 57% with pembrolizumab alone in the historical KEYNOTE-048 trial, representing a reduction in the risk of death compared to historical data. mOS of 32 months compared to 12.3 months in the historical KEYNOTE-048 trial. ORR of 50% in patients, including 50% with low PD-L1 expression CPS.